These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38036941)

  • 1. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
    Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan-amoxicillin dual therapy for
    Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
    Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Cheung KS; Lyu T; Deng Z; Han S; Ni L; Wu J; Tan JT; Qin J; Ng HY; Leung WK; Seto WK
    Helicobacter; 2024; 29(5):e13133. PubMed ID: 39244723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
    Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
    Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
    Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Ouyang Y; Wang M; Xu YL; Zhu Y; Lu NH; Hu Y
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1666-1672. PubMed ID: 35716370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
    Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
    Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG; Jiang X; Ding YB; She Q; Li YY
    Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
    Feng JH; Cheng J; Lao YJ; Huang K; Mou JL; Hu F; Lin ML; Lin J
    Eur J Med Res; 2023 Aug; 28(1):272. PubMed ID: 37550781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Hu Y; Huang XH; Zhou B; Liu ML; Liu YF; Yu T; Sun P; Tan BB; Hu Y; Cheng F; Pan XL; Hong JB; Shu X; Zhu Y; Lu NH
    Helicobacter; 2024; 29(1):e13045. PubMed ID: 39191423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
    Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
    Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
    J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Ju KP; Kong QZ; Li YY; Li YQ
    Helicobacter; 2024; 29(1):e13054. PubMed ID: 38900537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.